Tivic Health Systems, Inc. (TIVC)
NASDAQ: TIVC · Real-Time Price · USD
0.846
-0.005 (-0.54%)
At close: Mar 9, 2026, 4:00 PM EDT
0.784
-0.061 (-7.26%)
After-hours: Mar 9, 2026, 5:30 PM EDT
Company Description
Tivic Health Systems, Inc., a health tech company, develops and commercializes bioelectronic medicine.
Its primary product is ClearUP, a bioelectronic medicine for use in the treatment of sinus pain, pressure, and congestion.
The company sells its products through online retailers and commercial distributors, as well as its own website.
Its lead product candidate is Entolimod, a late-stage TLR5 agonist for use in the treatment of acute radiation syndrome.
In addition, the company markets its commercial product under the ClearUP Sinus Pain Relief brand name.
It also focusses on non-invasive vagus nerve stimulation. The company was incorporated in 2016 and is based in Fremont, California.
Tivic Health Systems, Inc.
| Country | United States |
| Founded | 2016 |
| IPO Date | Nov 11, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Jennifer Ernst |
Contact Details
Address: 47685 Lakeview Blvd. Fremont, California 94538 United States | |
| Phone | 888 276 6888 |
| Website | tivichealth.com |
Stock Details
| Ticker Symbol | TIVC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001787740 |
| CUSIP Number | 888705308 |
| ISIN Number | US8887053085 |
| Employer ID | 81-4016391 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Jennifer Ernst | Co-Founder, Chief Executive Officer and Director |
| Lisa G. Wolf | Chief Financial Officer and Principal Financial and Principal Accounting Officer |
| Michael Kevin Handley | Chief Operating Officer and President of Tivic Biopharma |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 4, 2026 | 8-K | Current Report |
| Feb 27, 2026 | SCHEDULE 13G | Filing |
| Feb 23, 2026 | 8-K/A | [Amend] Current report |
| Feb 9, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Feb 9, 2026 | 8-K | Current Report |
| Jan 20, 2026 | 424B3 | Prospectus |
| Jan 20, 2026 | 424B3 | Prospectus |
| Jan 20, 2026 | 8-K | Current Report |
| Jan 16, 2026 | EFFECT | Notice of Effectiveness |
| Jan 16, 2026 | EFFECT | Notice of Effectiveness |